Full metadata record
DC FieldValueLanguage
dc.creatorMorillas, C. (Carlos)-
dc.creatorEscalada, J. (Javier)-
dc.creatorPalomares, R. (Rafael)-
dc.creatorBellido, D. (Diego)-
dc.creatorGómez-Peralta, F. (F.)-
dc.creatorPérez, A. (Antonio)-
dc.date.accessioned2022-03-22T08:24:04Z-
dc.date.available2022-03-22T08:24:04Z-
dc.date.issued2019-
dc.identifier.citationMorillas, C. (Carlos); Escalada, J. (Javier); Palomares, R. (Rafael); et al. "Treatment of type 2 diabetes by patient profile in the clinical practice of endocrinology in Spain: Delphi study results from the think twice program". Diabetes Therapy. 10, 2019, 1893 - 1907es
dc.identifier.issn1869-6961-
dc.identifier.urihttps://hdl.handle.net/10171/63278-
dc.description.abstractIntroduction: The aim of this Delphi study is to unveil the management of patients with type 2 diabetes (T2D) and different levels of complexity in the clinical practice in Spain. Methods: Based on the common management practices of T2D profiles reported by Spanish endocrinologists, a Delphi questionnaire of 55 statements was developed and responded to by a national panel (n = 101). Results: A consensus was reached for 30 of the 55 statements. Regarding overweight patients inadequately controlled with metformin, treatment with a sodium-glucose transport protein 2 inhibitor (SGLT2-I) is preferred over treatment with a dipeptidyl peptidase-4 inhibitor (DPP4-I). If the patient is already being treated with a DPP4-I, an SGLT2-I is added on to the treatment regimen rather than replacing the DPP4-I. Conversely, if the treatment regimen includes a sulfonylurea, it is usually replaced by other antihyperglycemic agents. Current treatment trends in uncontrolled obese patients include the addition of an SGLT2-I or a glucagon-like peptide-1 receptor agonist (GLP1-RA) to background therapy. When the glycated hemoglobin target is not reached, triple therapy with metformin ? GLP1-RA ? SGLT2-I is initiated. Although SGLT2-Is are the treatment of choice in patients with T2D and heart failure or uncontrolled hypertension, no consensus was reached regarding the preferential use of SGLT2- Is or GLP1-RAs in patients with established cardiovascular disease. Conclusion: Consensus has been reached for a variety of statements regarding the management of several T2D profiles. Achieving a more homogeneous management of complex patients with T2D may require further evidence and a better understanding of the key drivers for treatment choice.es_ES
dc.description.sponsorshipLogistic support was provided by ESTEVE Pharmaceuticals S.A Spain.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Science and Business Media LLCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectClinical practicees_ES
dc.subjectComplex patientes_ES
dc.subjectDelphi questionnairees_ES
dc.subjectEndocrinologyes_ES
dc.subjectType 2 diabeteses_ES
dc.titleTreatment of type 2 diabetes by patient profile in the clinical practice of endocrinology in Spain: Delphi study results from the think twice programes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.es_ES
dc.identifier.doi10.1007/s13300-019-0671-x-
dadun.citation.endingPage1907es_ES
dadun.citation.publicationNameDiabetes Therapyes_ES
dadun.citation.startingPage1893es_ES
dadun.citation.volume10es_ES

Files in This Item:
Thumbnail
File
Morillas2019_Article_TreatmentOfType2DiabetesByPati.pdf
Description
Size
725.3 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.